Roquefort Therapeutics plc (LON:COIL – Get Free Report)’s stock price rose 2.9% during mid-day trading on Thursday . The stock traded as high as GBX 9 and last traded at GBX 9. 119,793 shares changed hands during mid-day trading, a decline of 43% from the average session volume of 209,281 shares. The stock had previously closed at GBX 8.75.
Roquefort Therapeutics Trading Down 10.0%
The stock has a market cap of £34.57 million, a P/E ratio of -0.37 and a beta of 0.05. The company has a current ratio of 0.63, a quick ratio of 3.07 and a debt-to-equity ratio of 8.18. The company has a 50-day moving average price of GBX 9.55 and a two-hundred day moving average price of GBX 9.60.
About Roquefort Therapeutics
Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications.
See Also
- Five stocks we like better than Roquefort Therapeutics
- GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue
- GTA VI’s Console Problem Isn’t Take-Two’s Problem
- Merchants Bancorp’s Rally Is Testing How Much Risk Investors Will Overlook
- Lululemon’s Earnings Beat Hid a Bigger Problem for Its Turnaround Story
Receive News & Ratings for Roquefort Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roquefort Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
